Clinical trials: Gastrointestinal Stromal Tumors
Gastrointestinal Stromal Tumor
Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery
This phase II trial is studying how well imatinib mesylate works in treating patients with gastrointestinal stromal tumor that was completely removed during surgery.
- Trial name
- NCT00025246
- Testing
- imatinib mesylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Gastrointestinal Stromal Tumor
Long Term Effects of Tyrosine Kinase Inhibitor Therapy on Ovarian Reserve and Fertility in Patients With Chronic Myeloid Leukemia or Gastrointestinal Stromal Tumor
This pilot research trial studies the long term effects of tyrosine kinase inhibitor therapy on ovarian reserve and fertility in patients with chronic myeloid leukemia or gastrointestinal stromal tumor.
- Conditions
- Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Gastrointestinal Stromal Tumor, Premenopausal
- Trial name
- NCT02734823
- Testing
- Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis, Questionnaire Administration
- Where
- United States
- Sponsor
- University of Southern California
Gastrointestinal Stromal Tumors
Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and Sunitinib
With discovery of KIT mutations and the advent of KIT tyrosine kinase inhibitor imatinib (GlivecTM, Novartis), there has been substantial improvement in overall survival in patients with advanced and/or metastatic…
- Trial name
- NCT02607332
- Testing
- Paclitaxel
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- Asan Medical Center
Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer
Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer
The purpose of this study is to show that the type, number and/or distribution of tumor metastases infiltrating immune cells such as cytotoxic T cells and/or the cytokine signature in the tumor metastases can be modulated by…
- Trial name
- Keynote-559 (NCT03168139)
- Testing
- Olaptesed pegol - Monotherapy, Olaptesed pegol + Pembrolizumab - Combination Therapy
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- TME Pharma AG
Gastrointestinal Stromal Tumors
Symptom Inventory for Gastrointestinal Stromal Tumors
The goal of this research study is to better understand the symptoms experienced by patients with GIST. There are 3 parts to this study.
- Trial name
- NCT01178307
- Testing
- Questionnaires, Interview, MDASI-GIST Questionnaire
- Where
- United States
- Volunteers
- 187 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Gastrointestinal Stromal Tumors
Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST)
This is a multicenter, post-marketing, clinical study evaluating the safety and efficacy of postoperative adjuvant therapy with Imatinib Mesylate in high-risk patients after curative resection of newly diagnosed GIST.Patients…
- Trial name
- NCT00171977
- Testing
- Imatinib Mesylate
- Where
- Japan
- Volunteers
- 64 people
- Sponsor
- Novartis Pharmaceuticals
Pleural Effusion, Malignant, Ascites, Malignant
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations…
- Conditions
- Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular
- Trial name
- TraveraRTGx (NCT05461430)
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Travera Inc
Gastrointestinal Neoplasm
Kinase Genotyping of Gastro Intestinal Stomach Tumors (GISTs) From Patients Enrolled in Pfizer A6181112 Phase IIIb Trial
The purpose of this study is to determine the genetic makeup of gastro intestinal stomach tumors (GISTs) from patients enrolled in the A6181112 phase IIIb trial.
- Trial name
- NCT00640692
- Sponsor
- Oregon Health and Science University
Gastrointestinal Stromal Tumors
Study of DCC-2618 in Patients With GIST After at Least 3 Prior Treatments
To evaluate the safety of DCC-2618 in patients with unresectable, metastatic, or recurrent gastrointestinal stromal tumor (GIST) who have received three or more prior therapies
- Trial name
- NCT07618377
- Testing
- DCC-2618
- Where
- 2 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Colorectal Cancer, Constipation, Impaction, and Bowel Obstruction
Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery
RATIONALE: Palliative therapy with octreotide may help patients who have bowel obstruction that cannot be removed by surgery to live longer and more comfortably.
- Conditions
- Colorectal Cancer, Constipation, Impaction, and Bowel Obstruction, Extrahepatic Bile Duct Cancer, Gastric Cancer
- Trial name
- NCT00004895
- Testing
- octreotide acetate
- Where
- United States
- Sponsor
- Northwestern University
Cancer
PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer
RATIONALE: PV701 may be able to kill tumor cells while leaving normal cells undamaged. PURPOSE: Phase I trial to study the effectiveness of PV701 in treating patients who have advanced or recurrent ovarian epithelial, fallopian…
- Trial name
- NCT00055705
- Testing
- PV701
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Gastrointestinal Stromal Tumor, Malignant
Correlation Between Imatinib Trough Concentration and Efficacy in Advanced GIST Patients with Different Genotypes
Imatinib (IM) has significantly enhanced the prognosis of patients (pts) with advanced gastrointestinal stromal tumors (GISTs). The clinical outcomes may correlate with IM exposure.
- Trial name
- NCT06628739
- Testing
- Imatinib
- Where
- China
- Volunteers
- 168 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
GIST
Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST Patients
The aim of this study is to evaluate the safety and efficacy of lenvatinib in patients with metastatic or advanced GIST who have failed at least imatinib, sunitinib, and regorafenib treatment.
- Trial name
- LONGIST (NCT07096609)
- Testing
- Lenvatinib Capsules
- Where
- South Korea
- Volunteers
- 48 people
- Sponsor
- Asan Medical Center
Gastrointestinal Stromal Tumors
Nilotinib Pharmacokinetics (PK) in Gastrointestinal Stromal Tumor (GIST): Nilotinib PK
In patients who are receiving nilotinib, nilotinib plasma levels will be measured after 1 month of nilotinib treatment. The relationship between surgery type and nilotinib pharmakokinetic properties will be investigated in this…
- Trial name
- NCT00976612
- Testing
- Nilotinib
- Where
- South Korea
- Volunteers
- 17 people
- Sponsor
- Asan Medical Center
Cancer
E-MOSAIC Electronic Tool to Monitor Symptoms
RATIONALE: A hand held electronic tool used to monitor symptoms and assess quality of life may improve communication between patients and their doctors and improve the ability to plan treatment for patients with advanced cancer…
- Trial name
- NCT00477919
- Where
- 7 sites in Switzerland
- Volunteers
- 264 people
- Sponsor
- Swiss Cancer Institute
Chronic Myeloid Leukemia, Gastrointestinal Stromal Tumors
Impact of the Inhibitors of Tyrosine Kinase on the Male Fertility
Evaluate the possible deleterious effects of tyrosine kinase inhibitors on sperm concentration, after 6 months of therapy, which corresponds to 2 cycles of spermatogenesis and on the sperm nuclear integrity.
- Trial name
- GLIFERTI (NCT01114087)
- Testing
- Imatinib treatment
- Where
- France
- Volunteers
- 2 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Gastrointestinal Stromal Tumors (GIST)
Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor
The mainstay of therapy for GISTs is surgical resection, however, recurrence is almost inevitable in high-risk tumors and secondary surgery or other salvage therapy has yielded poor outcome.
- Trial name
- NCT00633295
- Testing
- AMN107- NILOTINIB
- Where
- 3 sites in Israel
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals
Cancer
Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005860
- Testing
- floxuridine, leucovorin calcium, oxaliplatin
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Gastrointestinal Stromal Tumors
PDR001 Plus Imatinib for Metastatic or Unresectable GIST
Assuming that PDR001, an anti-PD-1 antibody, with imatinib might be effective in advanced GIST after failure of standard TKI therapies including imatinib, sunitinib, and regorafenib.
- Trial name
- NCT03609424
- Testing
- PDR001, Imatinib
- Where
- South Korea
- Volunteers
- 39 people
- Sponsor
- Asan Medical Center
Gastrointestinal Stromal Tumors
A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors
This is an open label, multi-center, phase II study of BBI503 administered to adult patients with advanced gastrointestinal stromal tumor who have exhausted all currently approved standard anti-cancer treatment options.
- Trial name
- NCT02232620
- Testing
- BBI503
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- Sumitomo Pharma America, Inc.